MARKET

LIFE

LIFE

Atyr Pharma Inc
NASDAQ
1.600
-0.020
-1.23%
Closed 17:57 04/19 EDT
OPEN
1.650
PREV CLOSE
1.620
HIGH
1.650
LOW
1.580
VOLUME
159.07K
TURNOVER
0
52 WEEK HIGH
2.700
52 WEEK LOW
1.080
MARKET CAP
108.71M
P/E (TTM)
-1.7021
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LIFE last week (0415-0419)?
Weekly Report · 10m ago
Weekly Report: what happened at LIFE last week (0408-0412)?
Weekly Report · 04/15 10:12
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
Weekly Report: what happened at LIFE last week (0401-0405)?
Weekly Report · 04/08 10:15
Weekly Report: what happened at LIFE last week (0325-0329)?
Weekly Report · 04/01 10:14
aTyr Pharma to Participate in April Investor Conferences
ATyr Pharma, Inc. Will participate in two upcoming investor conferences scheduled to take place in April 2024. The company is a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines. The company will be in San Diego.
Barchart · 04/01 07:00
Weekly Report: what happened at LIFE last week (0318-0322)?
Weekly Report · 03/25 10:16
WW, ATNM and XTIA are among pre market gainers
On the Move WW, ATNM and XTIA are among pre market gainers. Fusion Pharmaceuticals (FUSN) will buy Fusion pharmaceuticals for $2B. SCWorx (WORX) is up 18%. National Cinemedia (NCMI) gains 25%.
Seeking Alpha · 03/19 12:04
More
About LIFE
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.